Alcon revealed promising mid-term financial targets at its 2021 CMD. Sales momentum is set to accelerate – driven by increasing market penetration and new product launches in both segments – and the group is on track to outgrow the market. Importantly, steady margin expansion is also on the cards and along with the normalisation of capex should drive sustainable shareholder rewards. Thus, Alcon could be an attractive ophthalmology play for the post-pandemic world.
25 Mar 2021
Sales and margin profile set to inflect
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sales and margin profile set to inflect
Alcon revealed promising mid-term financial targets at its 2021 CMD. Sales momentum is set to accelerate – driven by increasing market penetration and new product launches in both segments – and the group is on track to outgrow the market. Importantly, steady margin expansion is also on the cards and along with the normalisation of capex should drive sustainable shareholder rewards. Thus, Alcon could be an attractive ophthalmology play for the post-pandemic world.